Teladoc Inc (TDOC) - Net Assets
Based on the latest financial reports, Teladoc Inc (TDOC) has net assets worth $1.39 Billion USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.88 Billion) and total liabilities ($1.49 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Teladoc Inc (TDOC) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.39 Billion |
| % of Total Assets | 48.36% |
| Annual Growth Rate | 48.64% |
| 5-Year Change | -90.61% |
| 10-Year Change | 735.04% |
| Growth Volatility | 416.2 |
Teladoc Inc - Net Assets Trend (2013–2024)
This chart illustrates how Teladoc Inc's net assets have evolved over time, based on quarterly financial data. See defensive interval ratio of Teladoc Inc to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Teladoc Inc (2013–2024)
The table below shows the annual net assets of Teladoc Inc from 2013 to 2024. For live valuation and market cap data, see market value of Teladoc Inc.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $1.49 Billion | -35.90% |
| 2023-12-31 | $2.33 Billion | +0.79% |
| 2022-12-31 | $2.31 Billion | -85.62% |
| 2021-12-31 | $16.05 Billion | +1.02% |
| 2020-12-31 | $15.88 Billion | +1466.41% |
| 2019-12-31 | $1.01 Billion | +0.09% |
| 2018-12-31 | $1.01 Billion | +81.27% |
| 2017-12-31 | $558.90 Million | +142.09% |
| 2016-12-31 | $230.87 Million | +29.29% |
| 2015-12-31 | $178.56 Million | +235.45% |
| 2014-12-31 | $53.23 Million | +179.35% |
| 2013-12-31 | $19.05 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Teladoc Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1617444700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $173.00K | 0.01% |
| Other Comprehensive Income | $-38.39 Million | -2.57% |
| Other Components | $17.76 Billion | 1191.03% |
| Total Equity | $1.49 Billion | 100.00% |
Teladoc Inc Competitors by Market Cap
The table below lists competitors of Teladoc Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Guangzhou Wondfo Biotech Co Ltd
SHE:300482
|
$1.33 Billion |
|
Labrador Iron Ore Royalty Corp
TO:LIF
|
$1.33 Billion |
|
Alimak Hek Group AB
ST:ALIG
|
$1.33 Billion |
|
Zhejiang Huangma Technology Co Ltd
SHG:603181
|
$1.33 Billion |
|
Beijing Jingwei Hirain Technologies Co. Ltd. A
SHG:688326
|
$1.32 Billion |
|
Prudent Corporate Advisory Services Limited
NSE:PRUDENT
|
$1.32 Billion |
|
Distribution Solutions Group Inc
NASDAQ:DSGR
|
$1.32 Billion |
|
Delong Composite Energy Group Co Ltd
SHE:000593
|
$1.32 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Teladoc Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,326,073,000 to 1,491,079,000, a change of -834,994,000 (-35.9%).
- Net loss of 1,001,245,000 reduced equity.
- Other comprehensive income decreased equity by 1,398,000.
- Other factors increased equity by 167,649,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-1.00 Billion | -67.15% |
| Other Comprehensive Income | $-1.40 Million | -0.09% |
| Other Changes | $167.65 Million | +11.24% |
| Total Change | $- | -35.90% |
Book Value vs Market Value Analysis
This analysis compares Teladoc Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.92x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 11.69x to 0.92x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | $0.69 | $8.07 | x |
| 2014-12-31 | $1.93 | $8.07 | x |
| 2015-12-31 | $8.97 | $8.07 | x |
| 2016-12-31 | $5.45 | $8.07 | x |
| 2017-12-31 | $10.08 | $8.07 | x |
| 2018-12-31 | $15.39 | $8.07 | x |
| 2019-12-31 | $14.11 | $8.07 | x |
| 2020-12-31 | $175.49 | $8.07 | x |
| 2021-12-31 | $102.24 | $8.07 | x |
| 2022-12-31 | $14.29 | $8.07 | x |
| 2023-12-31 | $14.13 | $8.07 | x |
| 2024-12-31 | $8.74 | $8.07 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Teladoc Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -67.15%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -38.97%
- • Asset Turnover: 0.73x
- • Equity Multiplier: 2.36x
- Recent ROE (-67.15%) is above the historical average (-70.08%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -31.59% | -30.24% | 0.73x | 1.44x | $-7.92 Million |
| 2014 | -32.01% | -39.14% | 0.47x | 1.73x | $-22.36 Million |
| 2015 | -32.49% | -74.98% | 0.34x | 1.29x | $-75.88 Million |
| 2016 | -32.15% | -60.26% | 0.41x | 1.32x | $-97.30 Million |
| 2017 | -19.11% | -45.77% | 0.28x | 1.48x | $-162.67 Million |
| 2018 | -9.58% | -23.23% | 0.27x | 1.51x | $-198.40 Million |
| 2019 | -9.75% | -17.87% | 0.35x | 1.58x | $-200.27 Million |
| 2020 | -3.05% | -44.35% | 0.06x | 1.12x | $-2.07 Billion |
| 2021 | -2.67% | -21.09% | 0.11x | 1.11x | $-2.03 Billion |
| 2022 | -591.90% | -567.53% | 0.51x | 2.04x | $-13.89 Billion |
| 2023 | -9.47% | -8.47% | 0.59x | 1.89x | $-452.98 Million |
| 2024 | -67.15% | -38.97% | 0.73x | 2.36x | $-1.15 Billion |
Industry Comparison
This section compares Teladoc Inc's net assets metrics with peer companies in the Health Information Services industry.
Industry Context
- Industry: Health Information Services
- Average net assets among peers: $315,296,744
- Average return on equity (ROE) among peers: -37.77%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Teladoc Inc (TDOC) | $1.39 Billion | -31.59% | 1.07x | $1.32 Billion |
| Aclarion Inc (ACON) | $2.23 Million | -317.55% | 0.31x | $1.82 Million |
| American Well Corp (AMWL) | $-204.41 Million | 0.00% | 0.00x | $126.97 Million |
| Heartbeam Inc (BEAT) | $310.49 Million | 13.79% | 0.89x | $40.74 Million |
| Bullfrog AI Holdings, Inc. Common Stock (BFRG) | $-540.52K | 0.00% | 0.00x | $6.51 Million |
| BrightSpring Health Services, Inc. Common Stock (BTSG) | $784.08 Million | -6.88% | 5.94x | $10.63 Billion |
| Carlsmed, Inc. Common Stock (CARL) | $-70.63 Million | 0.00% | 0.00x | $273.75 Million |
| CareCloud, Inc. (CCLD) | $41.72 Million | -116.68% | 0.87x | $92.63 Million |
| Certara Inc (CERT) | $492.77 Million | -6.75% | 1.13x | $881.63 Million |
| CareMax Inc (CMAX) | $6.73 Million | 88.33% | 4.72x | $381.50 |
| Claritev Corporation (CTEV) | $1.79 Billion | -32.00% | 3.12x | $460.29 Million |
About Teladoc Inc
Teladoc Health, Inc. provides virtual healthcare services worldwide. It operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals… Read more